文献速递免疫规划传染病防控与疫情报告

综合医疗系统中7077名5-11岁儿童接种辉瑞-BioNTech COVID-19 mRNA疫苗后的反应及相关就医情况

Reactions following Pfizer-BioNTech COVID-19 mRNA vaccination and related healthcare encounters among 7,077 children aged 5-11 years within an integrated healthcare system.
PubMed 文献 · Vaccine · 2022-11-03

本研究利用数字问卷和电子健康记录,对2021年11月4日至2022年2月28日期间在南加州Kaiser Permanente接种辉瑞-BioNTech COVID-19 mRNA疫苗的5-11岁儿童进行观察性研究。共纳入7077名参与者,第一剂后6247名有问卷应答者中2176人(35%)报告至少一种全身反应,第二剂后3401名应答者中1076人(32%)报告至少一种全身反应。接种后反应多为短暂且无需就医,未发现与心肌炎相关的就医。

要点

  • 第一剂后最常见反应为注射部位疼痛(48%)、疲劳(20%)、头痛(12%)、肌痛(9%)和发热(5%)。
  • 第二剂后局部反应报告率(33%)低于第一剂(50%),但发热报告率(9%)高于第一剂(5%)。
  • 胸痛或心动过速报告不频繁(1%),电子健康记录显示因接种后症状就医者中发热和恶心最常见,占比<0.5%,无心肌炎相关就医。

核心结论

  • 5-11岁儿童接种辉瑞-BioNTech COVID-19 mRNA疫苗后反应常见,但多数为短暂性且无需医疗照护。

研究设计与样本

  • 观察性研究,使用数字问卷和电子健康记录数据,纳入2021年11月4日至2022年2月28日期间在南加州Kaiser Permanente接种辉瑞-BioNTech COVID-19 mRNA疫苗的5-11岁儿童,共招募7077名参与者。

主要发现

  • 第一剂后6247名应答者中2176人(35%)报告至少一种全身反应;第二剂后3401名应答者中1076人(32%)报告至少一种全身反应。
  • 局部反应报告率第二剂后为33%(1113人),低于第一剂的50%(3140人)。
  • 第一剂后最常见反应为注射部位疼痛(48%)、疲劳(20%)、头痛(12%)、肌痛(9%)和发热(5%);第二剂后为注射部位疼痛(30%)、疲劳(19%)、头痛(13%)、肌痛(10%)和发热(9%)。
  • 接种后反应最常发生在接种后一天;胸痛或心动过速报告不频繁(1%)。
  • 电子健康记录显示因接种后症状就医者中,发热和恶心最常见,占儿童<0.5%,无心肌炎相关就医。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Studies combining data from digital surveys and electronic health records (EHR) can be used to conduct comprehensive assessments on COVID-19 vaccine safety. METHODS: We conducted an observational study using data from a digital survey and EHR of children aged 5-11 years vaccinated with Pfizer-BioNTech COVID-19 mRNA vaccine across Kaiser Permanente Southern California during November 4, 2021-February 28, 2022. Parents/guardians who enrolled their children were sent a 14-day survey on reactions. Survey results were combined with EHR, and medical encounters were described for children whose parents or guardians indicated seeking medical care for vaccine-related symptoms. This study describes self-reported reactions (local and systemic) and additional symptoms (chest pain, tachycardia, and pre-syncope). RESULTS: The study recruited 7,077 participants aged 5-11 years who received the Pfizer-BioNTech COVID-19 mRNA vaccine. Of 6,247 participants with survey responses after dose 1, 2,176 (35 %) reported at least one systemic reaction, and 1,076 (32 %) of 3,401 respondents following dose 2 reported at least one systemic reaction. Local reactions were reported less frequently following dose 2 (1,113, 33 %) than dose 1 (3,140, 50 %). The most frequently reported reactions after dose 1 were pain at the injection site (48 %), fatigue (20 %), headache (12 %), myalgia (9 %) and fever (5 %). The most frequently reported symptoms after dose 2 were also pain at the injection site (30 %), fatigue (19 %), headache (13 %), myalgia (10 %) and fever (9 %). Post-vaccination reactions occurred most frequently-one day following vaccination. Chest pain or tachycardia were reported infrequently (1 %). EHR demonstrated that parents rarely sought care for post-vaccination symptoms, and among those seeking care, the most common symptoms documented in EHR were fever and nausea, comprising <0.5 % of children. No encounters were related to myocarditis. CONCLUSION: While post-vaccination reactions to the Pfizer-BioNTech COVID-19 mRNA vaccine were common in children aged 5-11 years, our data showed that in most cases they were transient and did not require medical care.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Malden DE, Gee J, Glenn S, et al. Reactions following Pfizer-BioNTech COVID-19 mRNA vaccination and related healthcare encounters among 7,077 children aged 5-11 years within an integrated healthcare system. Vaccine. 2022. PMID: 36351861. doi:10.1016/j.vaccine.2022.10.079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。